Pierosandro Tagliaferri

发表

MMRF-CoMMpass Data Integration and Analysis for Identifying Prognostic Markers

Daniele Caracciolo, Marzia Settino, Mario Cannataro, 2020, ICCS.

DMETTM Genotyping: Tools for Biomarkers Discovery in the Era of Precision Medicine

Mario Cannataro, Giuseppe Agapito, Pietro Hiram Guzzi, 2020, High-throughput.

Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data

Mario Cannataro, Giuseppe Agapito, Mariamena Arbitrio, 2021, J. Comput. Sci..

Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case‐Control Study

Mario Cannataro, Giuseppe Agapito, Mariamena Arbitrio, 2019, Clinical pharmacology and therapeutics.

Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis

Mario Cannataro, Giuseppe Agapito, Pietro Hiram Guzzi, 2015, Cancer Chemotherapy and Pharmacology.

Synergistic Antitumor Activity of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib and IFN-α in Head and Neck Cancer Cells In vitro and In vivo

Michele Caraglia, Pierosandro Tagliaferri, Antonio Avallone, 2006, Clinical Cancer Research.

Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma

Mario Cannataro, Pietro Hiram Guzzi, Gareth J. Morgan, 2015, Oncotarget.

miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20/c-Rel/CTGF signaling

Pierosandro Tagliaferri, Pierfrancesco Tassone, Maria Teresa Di Martino, 2018, Journal of Experimental & Clinical Cancer Research.

IL-2 signals through Sgk1 and inhibits proliferation and apoptosis in kidney cancer cells

Vito Barbieri, Pierosandro Tagliaferri, Salvatore Venuta, 2007, Journal of Molecular Medicine.

Mir-221/222 are promising targets for innovative anticancer therapy

Marco Rossi, Pierosandro Tagliaferri, Pierfrancesco Tassone, 2016, Expert opinion on therapeutic targets.

Emerging pathways as individualized therapeutic target of multiple myeloma

Michele Caraglia, Pierosandro Tagliaferri, Pierfrancesco Tassone, 2013, Expert opinion on biological therapy.

Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: A DMET microarray profiling study

Mario Cannataro, Pietro Hiram Guzzi, Mariamena Arbitrio, 2011, Cancer biology & therapy.

miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies

Marco Rossi, Pierosandro Tagliaferri, Pierfrancesco Tassone, 2015, Oncotarget.

DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine

Mario Cannataro, Giuseppe Agapito, Pietro Hiram Guzzi, 2016, Oncotarget.

OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes

Mario Cannataro, Giuseppe Agapito, Pietro Hiram Guzzi, 2016, Microarrays.

A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling

Mario Cannataro, Pierangelo Veltri, Marco Rossi, 2011, British journal of haematology.

BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?

Mariamena Arbitrio, Pierosandro Tagliaferri, Pierfrancesco Tassone, 2009, Journal of ovarian research.

Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives

Mariamena Arbitrio, Licia Pensabene, Vito Barbieri, 2018, High-throughput.

Protein Arginine Methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in Multiple Myeloma

Kenneth C. Anderson, Nikhil C. Munshi, Mehmet Kemal Samur, 2017, Leukemia.